Moderna’s stock rallies as deal over a patent dispute clears vaccine pipeline

AirdropHarvester · 2026-03-04T04:03:57+00:00

Moderna's shares surged over 8% after the company announced a $950 million settlement with Arbutus Biopharma and Genevant Sciences to resolve COVID vaccine patent disputes, with an additional $1.3 billion to follow.

AirdropHarvester

2026-03-04 04:03:57

Abstract generation in progress

Shares of Moderna jumped more than 8% in the extended session Tuesday as the pharmaceutical company said it has reached a deal to resolve a dispute related to its COVID vaccine.

Moderna MRNA said late Tuesday it has agreed to pay biotech companies Arbutus Biopharma ABUS and Genevant Sciences, which is privately held, $950 million upfront and an additional $1.3 billion to end their patent disputes.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.